DK1761266T3 - Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme - Google Patents

Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme

Info

Publication number
DK1761266T3
DK1761266T3 DK05754754.9T DK05754754T DK1761266T3 DK 1761266 T3 DK1761266 T3 DK 1761266T3 DK 05754754 T DK05754754 T DK 05754754T DK 1761266 T3 DK1761266 T3 DK 1761266T3
Authority
DK
Denmark
Prior art keywords
formulations
treating
compounds
methods
skin diseases
Prior art date
Application number
DK05754754.9T
Other languages
English (en)
Inventor
Jack A Dejovin
Thomas M Rossi
Original Assignee
Galderma Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/853,585 external-priority patent/US7439241B2/en
Application filed by Galderma Pharma Sa filed Critical Galderma Pharma Sa
Application granted granted Critical
Publication of DK1761266T3 publication Critical patent/DK1761266T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK05754754.9T 2004-05-25 2005-05-25 Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme DK1761266T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57414204P 2004-05-25 2004-05-25
US10/853,585 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
PCT/US2005/018288 WO2005115395A2 (en) 2004-05-25 2005-05-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders

Publications (1)

Publication Number Publication Date
DK1761266T3 true DK1761266T3 (da) 2013-08-05

Family

ID=35451386

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05754754.9T DK1761266T3 (da) 2004-05-25 2005-05-25 Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme

Country Status (15)

Country Link
EP (2) EP1761266B1 (da)
JP (2) JP4955543B2 (da)
KR (1) KR101257046B1 (da)
CN (2) CN101426502A (da)
AU (1) AU2005247467B2 (da)
BR (1) BRPI0511519A (da)
CA (2) CA2824612C (da)
DK (1) DK1761266T3 (da)
ES (2) ES2647618T3 (da)
MX (1) MXPA06013649A (da)
NZ (1) NZ552325A (da)
PL (1) PL1761266T3 (da)
PT (1) PT1761266E (da)
SI (1) SI1761266T1 (da)
WO (1) WO2005115395A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
CA2779063A1 (en) * 2009-10-26 2011-05-05 Galderma Pharma S.A. Methods of treating or preventing acute erythema
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
KR20150058551A (ko) 2010-03-26 2015-05-28 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
US8513247B2 (en) * 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US8501796B2 (en) * 2010-09-16 2013-08-06 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
EP2605753A2 (en) * 2010-10-21 2013-06-26 Galderma S.A. Topical gel composition
PH12013500738A1 (en) 2010-10-21 2016-08-05 Galderma Sa Brimonidine gel compositions and methods of use
CN101972272B (zh) * 2010-10-31 2012-07-04 无锡龙腾画材有限公司 一种二氧化氯皮肤凝胶及其制备方法
KR20210080591A (ko) * 2010-11-16 2021-06-30 알러간, 인코포레이티드 (3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐)메탄올을 포함하는 약제학적 조성물
KR102058756B1 (ko) * 2011-02-15 2020-01-22 어클라리스 쎄라퓨틱스, 인코포레이티드 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
MX2014004383A (es) * 2011-10-19 2014-11-12 Galderma Sa Metodo para reducir el enrojecimiento facial asociado con el uso sistemico de inhibidores de fosfodiesterasa tipo 5.
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
WO2013078151A1 (en) 2011-11-21 2013-05-30 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
RU2015148910A (ru) * 2013-05-06 2017-06-13 Аллерган, Инк. Альфа-адренергические агонисты для лечения повреждения тканей
JP2016525553A (ja) * 2013-07-26 2016-08-25 ガルデルマ・リサーチ・アンド・デヴェロップメント 皮膚肥厚の治療法
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
RU2018105761A (ru) 2013-10-07 2019-02-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
US9937117B2 (en) * 2015-07-09 2018-04-10 Galderma S.A. Method of reducing hair loss associated with chemotherapy
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
KR20210113439A (ko) 2016-10-31 2021-09-15 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
CN106727462B (zh) * 2016-11-14 2019-04-09 四川省人民医院 一种治疗面部皮炎的药物及其应用
JP2022516796A (ja) * 2019-01-12 2022-03-02 セリックス バイオ プライヴェート リミテッド 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用
US20220218590A1 (en) * 2019-05-14 2022-07-14 Abend Fritz Ventures Llc Compositions and methods for removal of skin adhesive patches, products, and residual adhesives
EP4203958A4 (en) * 2020-08-26 2024-10-09 Oticara, Inc. COMPOSITIONS, DEVICES AND METHODS FOR TREATING NOSE, EAR AND OTHER TISSUE INFECTIONS AND/OR INFECTIONS

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
IL92351A (en) 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5910312A (en) * 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
JPH1129482A (ja) * 1997-05-14 1999-02-02 Taisho Pharmaceut Co Ltd 医薬組成物
KR20010032435A (ko) * 1997-11-24 2001-04-25 데이비드 엠 모이어 5-(2-이미다졸리닐아미노)벤즈이미다졸 유도체, 그의 제조및 대사 안정성이 개선된 알파-아드레날린수용체아고니스트로서의 그의 용도
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
IN185228B (da) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
JP4927298B2 (ja) * 2000-07-14 2012-05-09 アラーガン、インコーポレイテッド α−２−アドレナリンアゴニスト成分を含有する組成物
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
JP3520076B2 (ja) * 2001-10-02 2004-04-19 憲司 中村 皮膚外用剤
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Also Published As

Publication number Publication date
NZ552325A (en) 2010-11-26
CN101426502A (zh) 2009-05-06
WO2005115395A3 (en) 2009-04-09
CA2567401A1 (en) 2005-12-08
JP5547705B2 (ja) 2014-07-16
EP1761266A2 (en) 2007-03-14
PL1761266T3 (pl) 2013-09-30
KR101257046B1 (ko) 2013-04-22
AU2005247467B2 (en) 2010-12-02
CA2567401C (en) 2013-11-12
JP2008500356A (ja) 2008-01-10
JP4955543B2 (ja) 2012-06-20
BRPI0511519A (pt) 2007-12-26
SI1761266T1 (sl) 2013-08-30
EP1761266B1 (en) 2013-05-08
MXPA06013649A (es) 2007-07-09
ES2424644T3 (es) 2013-10-07
WO2005115395A2 (en) 2005-12-08
EP2481412A1 (en) 2012-08-01
KR20070032716A (ko) 2007-03-22
AU2005247467A1 (en) 2005-12-08
PT1761266E (pt) 2013-06-04
EP2481412B1 (en) 2017-09-27
CN104490884A (zh) 2015-04-08
JP2012072176A (ja) 2012-04-12
EP1761266A4 (en) 2009-11-11
CA2824612A1 (en) 2005-12-08
CA2824612C (en) 2016-08-16
ES2647618T3 (es) 2017-12-22

Similar Documents

Publication Publication Date Title
SI1761266T1 (sl) Spojine, formulacije in postopki za zdravljenje ali preprečevanje vnetnih kožnih motenj
IS7684A (is) Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK1830869T3 (da) Fremgangsmåde til behandling eller profylakse
DK1830843T3 (da) Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme
DK1583542T3 (da) Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK1951866T3 (da) Delta-9-elongaser og anvendelse heraf til fremstilling af flerumættede fedtsyrer
DK1830838T3 (da) Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
DE602005027052D1 (de) Endoskopbehandlungssystem
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
DK1667730T3 (da) Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
EP1954571A4 (en) RETRACTABLE POLYLACTIC ACID FILMS AND METHODS OF MOLDING THEM
DK1809328T3 (da) Mannooligosaccharid-sammensætning til kropsfedt-reduktion
DK1863899T3 (da) Hudbehandlingspræparater
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
DE602004029376D1 (de) Fettzusammensetzung für backware, sowie backware
DK1734959T3 (da) Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter
DK2119472T3 (da) Hud-/hårbehandlingssystem
IS7572A (is) Aðferð og efni til lækninga